Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis

Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis

Abstract Background We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O). Methods We studied etanercept-naive participants with RA from four Canadian prospective cohorts...

Full description

Saved in:
Bibliographic Details
Main Authors: Marina G. Birck, Jessica Boivin, Laura Yan, Nathalie Carrier, Cristiano S. Moura, Walter P. Maksymowych, Gilles Boire, Denis Choquette, Luck Lukusa, Michael Mallinson, Linda Wilhelm, Autumn Neville, Sasha Bernatsky
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Etanercept
Remission induction
Biosimilar pharmaceuticals
Online Access:https://doi.org/10.1186/s13075-025-03607-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13075-025-03607-7

Similar Items